Understanding vaccine safety information from the vaccine adverse event reporting system

被引:291
作者
Varricchio, F [1 ]
Iskander, J
Destefano, F
Ball, R
Pless, R
Braun, MM
Chen, RT
机构
[1] Food & Drug Adm, Ctr Biol Evaluat & Res, Off Biostat & Epidemiol, Div Epidemiol, Ottawa, ON, Canada
[2] CDCP, Natl Immunizat Program, Epidemiol & Surveillance Div, Immunizat Safety Branch, Ottawa, ON, Canada
[3] Hlth Canada, Ctr Infect Dis Prevent & Control, Immunizat & Resp Infect Div, Immunizat Safety Unit, Ottawa, ON K1A 0L2, Canada
关键词
adverse event; vaccine; vaccine adverse event reporting system (VAERS);
D O I
10.1097/00006454-200404000-00002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Vaccine Adverse Event Reporting System (VAERS) is administered by the Food and Drug Administration and CDC and is a key component of postlicensure vaccine safety surveillance. Its primary function is to detect early warning signals and generate hypotheses about possible new vaccine adverse events or changes in frequency of known ones. VAERS is a passive surveillance system that relies on physicians and others to voluntarily submit reports of illness after vaccination. Manufacturers are required to report all adverse events of which they become aware. There are a number of well-described limitations of such reporting systems. These include, for example, variability in report quality, biased reporting, underreporting and the inability to determine whether a vaccine caused the adverse event in any individual report. Strengths of VAERS are that it is national in scope and timely. The information in VAERS reports is not necessarily complete nor is it verified systematically. Reports are classified as serious or nonserious based on regulatory criteria. Reports are coded by VAERS in a uniform way with a limited number of terms using a terminology called COSTART. Coding is useful for search purposes but is necessarily imprecise. VAERS is useful in detecting adverse events related to vaccines and most recently was used for enhanced reporting of adverse events in the national smallpox immunization campaign. VAERS data have always been publicly available. However, it is essential for users of VAERS data to be fully aware of the strengths and weaknesses of the system. VAERS data contain strong biases. Incidence rates and relative risks of specific adverse events cannot be calculated. Statistical significance tests and confidence intervals should be used with great caution and not routinely. Signals detected in VAERS should be subjected to further clinical and descriptive epidemiologic analysis. Confirmation in a controlled study is usually required. An understanding of the system's defined objectives and inherent drawbacks is vital to the effective use of VAERS data in vaccine safety investigations.
引用
收藏
页码:287 / 294
页数:8
相关论文
共 50 条
  • [21] Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990-2016
    Moro, Pedro L.
    Zheteyeva, Yenlik
    Barash, Faith
    Lewis, Paige
    Cano, Maria
    [J]. VACCINE, 2018, 36 (01) : 50 - 54
  • [22] Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children Analysis of the Vaccine Adverse Event Reporting System
    Muhammad, Riyadh D.
    Haber, Penina
    Broder, Karen R.
    Leroy, Zanie
    Ball, Robert
    Braun, M. Miles
    Davis, Robert L.
    McMahon, Ann W.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (01) : E1 - E8
  • [23] The temporal relationship between RotaTeq immunization and intussusception adverse events in the Vaccine Adverse Event Reporting System (VAERS)
    Geier, David A.
    King, Paul G.
    Sykes, Lisa K.
    Geier, Mark R.
    [J]. MEDICAL SCIENCE MONITOR, 2012, 18 (02): : PH12 - PH17
  • [24] Human papilloma virus vaccination in males: A pharmacovigilance study on the Vaccine Adverse Event Reporting System
    Bonaldo, Giulia
    Montanaro, Nicola
    Vaccheri, Alberto
    Motola, Domenico
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (04) : 1912 - 1917
  • [25] Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System
    Mei, Riccardo
    Raschi, Emanuel
    Forcesi, Emanuele
    Diemberger, Igor
    De Ponti, Fabrizio
    Poluzzi, Elisabetta
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 273 : 183 - 186
  • [26] Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017-April 2024
    Shu, Yamin
    Cheng, Wenxin
    He, Xucheng
    Huang, Liu
    Chen, Wei
    Zhang, Qilin
    [J]. PREVENTIVE MEDICINE REPORTS, 2025, 50
  • [27] Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: Reports to the vaccine adverse event reporting system
    Ball, R
    Ball, LK
    Wise, RP
    Braun, MM
    Beeler, JA
    Salive, ME
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (02) : 219 - 223
  • [28] Motor palsies of cranial nerves (excluding VII) after vaccination Reports to the US Vaccine Adverse Event Reporting System
    Woo, Emily Jane
    Winiecki, Scott K.
    Ou, Alan C.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (02) : 301 - 305
  • [29] Post-vaccination headache reporting: Trends according to the Vaccine Adverse Events Reporting System
    Cocores, Alexandra N.
    Goadsby, Peter J.
    Monteith, Teshamae S.
    [J]. HEADACHE, 2023, 63 (02): : 275 - 282
  • [30] Rubella vaccine and arthritic adverse reactions: An analysis of the Vaccine Adverse Events Reporting System (VAERS) database from 1991 through 1998
    Geier, DA
    Geier, MR
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2001, 19 (06) : 724 - 726